Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Interest Expenses (2021 - 2026)

DiaMedica Therapeutics filings provide 6 years of Interest Expenses readings, the most recent being $23000.0 for Q1 2026.

  • Quarterly Interest Expenses rose 2200.0% to $23000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23000.0 through Mar 2026, up 2200.0% year-over-year, with the annual reading at $10000.0 for FY2025, 70.59% down from the prior year.
  • Interest Expenses hit $23000.0 in Q1 2026 for DiaMedica Therapeutics, up from $1000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $28.0 million in Q4 2023 and bottomed at $1000.0 in Q1 2025.
  • Average Interest Expenses over 5 years is $10.2 million, with a median of $23000.0 recorded in 2026.
  • The largest annual shift saw Interest Expenses crashed 94.74% in 2025 before it surged 2200.0% in 2026.
  • DiaMedica Therapeutics' Interest Expenses stood at $22.7 million in 2022, then rose by 23.32% to $28.0 million in 2023, then tumbled by 99.93% to $19000.0 in 2024, then crashed by 94.74% to $1000.0 in 2025, then surged by 2200.0% to $23000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Interest Expenses are $23000.0 (Q1 2026), $1000.0 (Q1 2025), and $19000.0 (Q1 2024).